Lara-Cerrillo Sandra, Urda Muñoz Cristina, de la Casa Heras Moisés, Camacho Fernández-Pacheco Silvia, Gijón de la Santa Julio, Lacruz-Ruiz Tania, Rosado-Iglesias Candela, Gonçalves-Aponte Verónica, Badajoz Liébana Vicente, García-Peiró Agustín
CIMAB, Barcelona Male Infertility Centre, Sant Quirze del Vallés, Barcelona, Spain; Departament de Biologia Cel·lular, Fisiologia i Immunologia, Facultat de Medicina, Universitat Autònoma de Barcelona (UAB), Bellaterra, Barcelona, Spain.
Clínica GINEFIV, General Life IVF, Madrid, Spain.
Rev Int Androl. 2023 Jan-Mar;21(1):100338. doi: 10.1016/j.androl.2021.10.003. Epub 2022 Nov 2.
Delays in embryo kinetics, implantation failures in ICSI treatments and recurrent miscarriages have been associated with high values of Double-Strand Breaks (DSB) in sperm DNA. While conventional methods for semen preparation have been shown to be inefficient reducing DSB values, Microfluidic Sperm Sorting (MSS) devices are promising tools to reduce this damage.
To study the clinical utility of an MSS device in ICSI treatments when the male partner presents increased DSB values, as compared to the use of conventional methods based on sperm motility.
This retrospective cohort study included 28 infertile couples undergoing ICSI treatments. Only couples where the male partner presented increased values of DSB were included. DSB values were evaluated in semen samples by the Neutral Comet assay. Couples performed a first ICSI cycle using conventional methods for semen preparation (Density Gradients and Swim-up) and a second ICSI cycle using the ZyMōt™ICSI (formerly named FertileChip®) microfluidic device. Embryology and clinical outcomes were compared between ICSI cycles.
Semen parameters and the number of obtained and fertilized oocytes did not show differences between ICSI rounds. Clinical outcomes were statistically better when MSS was used: the biochemical pregnancy rate increased 28.31%; the clinical pregnancy rate increased 35.56% and the number of live births increased 35.29%, as compared to the first ICSI cycle in this group of patients.
The ZyMōt™ICSI microfluidic device improved the reproductive outcomes in couples where the male partner presented increased DSB values, when compared to the use of conventional semen preparation techniques.
胚胎动力学延迟、卵胞浆内单精子注射(ICSI)治疗中的植入失败以及复发性流产与精子DNA中双链断裂(DSB)的高值有关。虽然传统的精液制备方法已被证明在降低DSB值方面效率低下,但微流控精子分选(MSS)设备是减少这种损伤的有前景的工具。
研究当男性伴侣的DSB值升高时,与基于精子活力的传统方法相比,MSS设备在ICSI治疗中的临床效用。
这项回顾性队列研究纳入了28对接受ICSI治疗的不育夫妇。仅纳入男性伴侣DSB值升高的夫妇。通过中性彗星试验评估精液样本中的DSB值。夫妇们进行了第一个使用传统精液制备方法(密度梯度离心法和上游法)的ICSI周期,以及第二个使用ZyMōt™ ICSI(原名FertileChip®)微流控设备的ICSI周期。比较了ICSI周期之间的胚胎学和临床结局。
ICSI轮次之间的精液参数以及获得的和受精的卵母细胞数量没有差异。使用MSS时临床结局在统计学上更好:与该组患者的第一个ICSI周期相比,生化妊娠率提高了28.31%;临床妊娠率提高了35.56%,活产数量增加了35.29%。
与使用传统精液制备技术相比,ZyMōt™ ICSI微流控设备改善了男性伴侣DSB值升高的夫妇的生殖结局。